Antibodies

28 Nov 2018 Augie's Quest Reports First Subject Successfully Enrolled in AT-1501 Phase 1 Study, a First-of-its-Kind, Promising Treatment for ALS
28 Nov 2018 Daiichi Sankyo Launches Antitumor Agent Trastuzumab Biosimilar for Intravenous Drip Infusions “Daiichi Sankyo” in Japan
27 Nov 2018 Forbius’ AVID200, a novel TGF-beta 1 & 3 Inhibitor, Cleared by the FDA to Commence Phase 1 Clinical Trial in Solid Tumors
27 Nov 2018 OSE Immunotherapeutics Receives Belgian Authorization for a Phase 1 Clinical Trial to Evaluate Anti-IL-7 Receptor Antagonist OSE-127
27 Nov 2018 Bristol-Myers Squibb Announces CheckMate -451 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo Plus Yervoy Vs. Placebo as A Maintenance Therapy in Patients with Extensive-Stage Small Cell Lung Cancer After Completion of First-Line Chemo
26 Nov 2018 FDA Approves The ACTpen For Genentech’s ACTEMRA, A Single-Dose, Prefilled Autoinjector For The Treatment Of Rheumatoid Arthritis, Giant Cell Arteritis And Two Forms Of Juvenile Arthritis
21 Nov 2018 Bioasis Announces Positive Results from Peripheral Whole-Body PET/CT Scan Study in Non-Human Primates with Lead Investigational Candidate xB3-001™
21 Nov 2018 FDA approves Gamifant® (emapalumab), the first and only treatment for primary haemophagocytic lymphohistiocytosis (HLH)
20 Nov 2018 OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Initiation of Phase 2 Clinical Trial to Evaluate Tedopi® in Combination with Opdivo® (nivolumab) in Pancreatic Cancer
20 Nov 2018 Formycon Releases Updates on Development Programs and Milestones
19 Nov 2018 CHMP Issues Positive Opinion on Split Dosing Regimen for DARZALEX® (daratumumab)
19 Nov 2018 Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
19 Nov 2018 Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
18 Nov 2018 Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
18 Nov 2018 Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas
16 Nov 2018 Visterra Presents Data Demonstrating Safety, Tolerability and Positive Clinical Activity Trends of VIS410 in Non-Hospitalized Patients with Influenza A
16 Nov 2018 Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab) as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
16 Nov 2018 FDA Grants Breakthrough Therapy Designation to ADCETRIS® (Brentuximab Vedotin) for Frontline Peripheral T-Cell Lymphomas
16 Nov 2018 Shire Announces New HELP Study™ Data for Lanadelumab in Hereditary Angioedema (HAE) at 2018 ACAAI Annual Scientific Meeting
16 Nov 2018 AstraZeneca provides update on the Phase III MYSTIC trial of Imfinzi and tremelimumab in Stage IV non-small cell lung cancer
15 Nov 2018 MacroGenics Announces Poster Presentation on Preclinical PD-L1 x CD137 DART® Program at the EORTC-NCI-AACR Symposium in Dublin
15 Nov 2018 Five Prime Therapeutics Initiates Patient Dosing in a Phase 1 Clinical Trial of FPT155, a First-in-Class CD80 Fusion Protein
14 Nov 2018 Zymeworks Announces Updated Clinical Data for Novel Bispecific Antibody, ZW25, Presented at the EORTC-NCI-AACR Symposium
14 Nov 2018 Seattle Genetics Initiates Phase 1 Clinical Trial of SEA-BCMA for Patients with Relapsed or Refractory Multiple Myeloma
14 Nov 2018 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top